BioNTech Slashes 2026 Revenue Outlook to €2B-€2.3B
BNTX is trading near its 52-week low of $79.52 (9.4% above the low).
Summary
BioNTech has revised its 2026 revenue guidance to €2B-€2.3B, a significant cut from prior expectations, while also lowering its 2026 adjusted R&D expense forecast to €2B-€2.3B from a previous range of €2.2B-€2.5B. The revision is driven by weaker-than-anticipated COVID-19 vaccine demand and the timing of licensing deal payments, with the company no longer expecting milestone-related revenue from an outlicensed program in 2026. This follows a CEO transition announced yesterday, with Guido Oelkers appointed as CEO effective by February 1, 2027, and a $1B buyback launched in June. The company faces a Q2 loss forecast of €2.09 per share on just €157.7M in revenue, underscoring its struggle to replace COVID-19 vaccine revenues and raising doubts about the near-term commercial impact of its oncology pipeline. With shares at $87.03 and a $23B market cap, the guidance reset may force analysts to reassess the path to profitability, and the new CEO faces immediate pressure to restore confidence when Q2 results are reported.
At the time of this announcement, BNTX was trading at $87.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3B. The 52-week trading range was $79.52 to $124.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.